Vasopressin vs Terlipressin: What the Research Compares

Vasopressin and terlipressin are prescription medicines, dispensed and administered under clinician supervision in hospital settings, and both belong to the vasopressin receptor agonist class rather than the catecholamine class. Readers comparing the two usually want to know whether published research has placed them side by side in the same trial, and what each body of evidence actually measured. This page answers that question from the published record only. It describes what studies examined and reported, and it does not rank the agents, declare a preferred option, or suggest how either should be used. This page is for educational purposes only and is not medical advice; consult a licensed physician or another qualified prescriber for any question about treatment.

Is There a Head-to-Head Randomized Trial?

Within the verified citation set used for this page, no publication reported a randomized controlled trial that enrolled a single patient population, assigned one arm to vasopressin and a second arm to terlipressin, and measured a shared primary endpoint. That is stated plainly because the absence of a direct comparison shapes everything else on this page. Where no head-to-head trial exists, any statement that one agent outperformed the other would be an inference across separate populations, protocols and outcome definitions, not a trial result.

Two sources in the set come closest to comparative analysis. A 2024 meta-analysis of randomized controlled trials examined non-adrenergic vasopressors in vasodilatory shock and perioperative vasoplegia, a category defined by agents acting outside the catecholamine pathway (PMID 39736782). A 2023 network meta-analysis of vasopressors in septic shock applied a network framework, which combines direct and indirect evidence across trials to compare multiple agents on efficacy and safety outcomes (PMID 37548686). Network and pooled analyses of this kind assemble separate trials rather than randomizing patients between the two specific agents, so researchers describing them generally caution that indirect estimates depend on the comparability of the included populations.

Older and broader syntheses provide the background against which both agents are discussed. A Cochrane review of vasopressors for shock surveyed the randomized evidence available at the time of publication (PMID 15266497), and a 2015 systematic review and meta-analysis focused specifically on vasopressors for the treatment of septic shock (PMID 26237037). A 2024 systematic review of interventions affecting mortality in sepsis looked beyond guideline-endorsed bundles at the wider trial literature on sepsis outcomes (PMID 38093626).

Separate Evidence Bases, Side By Side

Because the direct comparison does not exist in this citation set, the most accurate framing is two distinct literatures that overlap in pharmacology but diverge in the clinical questions researchers have asked. The table below summarises that separation. Each cell reflects what the cited papers examined, not a judgement about relative performance.

The practical consequence is that the two agents have been asked to answer different research questions. Shock trials in critical care have generally measured haemodynamic response, catecholamine requirement and mortality (PMID 38093626), while the hepatology literature has centred on kidney function in hepatorenal syndrome and on bleeding control in portal hypertension (PMID 37258014, PMID 33723542). Endpoints defined that differently are not interchangeable.

Class and Mechanism as Described in Reviews

Both agents act through vasopressin receptors, which is why reviews group them apart from adrenergic vasopressors such as norepinephrine. The 2024 meta-analysis of non-adrenergic vasopressors framed the whole category around agents that raise vascular tone without relying on adrenergic receptor stimulation, a pharmacological distinction that matters when trials pool agents with different receptor targets (PMID 39736782). Reviews of vasoplegic syndrome after cardiovascular surgery have described the same rationale in the perioperative context, where profound vasodilation can persist despite adrenergic support (PMID 34251716).

Terlipressin is described in hepatorenal syndrome reviews as a synthetic analogue of vasopressin used in the management of circulatory changes associated with advanced liver disease, where splanchnic vasodilation is a central feature of the pathophysiology the review set out (PMID 37258014). In acute variceal bleeding, researchers have studied vasoactive agents for their effect on portal and splanchnic circulation, and the 2021 systematic review and meta-analysis assembled randomized evidence on that class of agents (PMID 33723542).

Regulatory Status

Both compounds are regulated as prescription medicines. Vasopressin is marketed as an approved injectable prescription product in the United States for use in vasodilatory shock, and it is also prepared and administered in hospital pharmacy practice under prescription control. Terlipressin is an approved prescription medicine in the United States for adults with hepatorenal syndrome accompanied by rapid reduction in kidney function, and it is registered in numerous other countries, including for use in portal hypertension related bleeding. Approved labelling, indications and restrictions differ by country and by product, and only a prescribing clinician can determine whether any approved indication applies to an individual patient. Nothing on this page describes an administration schedule, and the cited papers are summarised here for their study design and findings rather than as guidance.

How Researchers Measured Effect

Comparing vasopressor literature requires attention to the outcome scales used. The vasoactive-inotropic score, reviewed in 2021 for its evolution, clinical utility and pitfalls, aggregates multiple vasoactive infusions into a single numerical value, and the review set out the limitations that arise when agents with different potencies and receptor profiles are summed into one score (PMID 33069558). That caveat is directly relevant to any attempt to read across between vasopressin trials and terlipressin trials, because a composite score may not weight non-adrenergic agents in a way that supports fine-grained comparison.

Reviews of vasopressor refinement in septic shock have also discussed the shift from single-agent thinking toward multi-receptor strategies and earlier adjunct use, which changes what a trial endpoint represents across publication eras (PMID 35836635). The 2004 Cochrane review and the 2023 network meta-analysis therefore reflect different practice backgrounds, a point that limits naive pooling across decades (PMID 15266497, PMID 37548686).

Population differences matter as well. A 2024 update on pharmacologic management of neonatal hypotension reviewed when and why specific agents have been studied in neonates, a population with circulatory physiology distinct from adult septic shock cohorts (PMID 38671707).

Vasopressin and Terlipressin Adverse Events: What Studies Report

Safety has been examined inside the same syntheses that examined efficacy rather than in dedicated head-to-head safety trials. The 2023 network meta-analysis of vasopressors in septic shock addressed both efficacy and safety outcomes across the agents it included (PMID 37548686), and the 2024 meta-analysis of non-adrenergic vasopressors in vasodilatory shock and perioperative vasoplegia likewise pooled randomized trial data on outcomes associated with these agents (PMID 39736782).

A recognised hazard across the vasopressor class is local tissue injury when an infusion leaks from the vein. A 2023 focused update reviewed the management of noncytotoxic extravasation injuries and covered treatment strategies and the peripheral administration of vasopressors and hypertonic saline, which is the setting in which such injuries are most often described (PMID 36938775). Reviews of vasoplegic syndrome following cardiovascular surgery have discussed outcome-oriented therapeutic management, including the trade-offs that accompany escalating vasoactive support (PMID 34251716).

On the hepatology side, the 2021 systematic review and meta-analysis of vasoactive agents for acute variceal bleeding assessed the randomized evidence on these agents, including safety considerations reported in the included trials (PMID 33723542), and the 2023 hepatorenal syndrome review discussed treatment within the broader clinical picture of advanced liver disease, where circulatory and kidney function are already compromised (PMID 37258014). Individual risk profiles are a matter for the treating clinician, who can weigh the published safety signals against a specific patient's physiology.

What the Comparison Can and Cannot Support

• No randomized head-to-head trial of vasopressin against terlipressin appears in the verified papers cited here, so no direct comparative claim can be made from this set.
• Pooled and network analyses in shock populations include non-adrenergic vasopressors as a category and report efficacy and safety outcomes at that level (PMID 39736782, PMID 37548686).
• Terlipressin research in this set is concentrated in liver-related indications rather than general critical care shock trials (PMID 37258014, PMID 33723542).
• Composite outcome scores used in critical care carry documented limitations when agents with differing receptor profiles are compared (PMID 33069558).
• Sepsis trial literature has evolved over time, so synthesis era affects interpretation (PMID 15266497, PMID 38093626).

Related reading: Vasopressin overview.

References

• Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials (Critical Care, 2024)
• The Efficacy and Safety of Vasopressors for Septic Shock Patients: A Systemic Review and Network Meta-analysis (Shock, 2023)
• Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis (PLoS One, 2015)
• Vasopressors for shock (Cochrane Database of Systematic Reviews, 2004)
• Vasopressors in Septic Shock: The Quest for Refinement (Indian Journal of Critical Care Medicine, 2022)
• Beyond the Surviving Sepsis Campaign Guidelines: a systematic review of interventions affecting mortality in sepsis (Panminerva Medica, 2024)
• Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment (Medical Clinics of North America, 2023)
• Vasoactive Agents for the Management of Acute Variceal Bleeding: A Systematic Review and Meta-analysis (Journal of Gastrointestinal and Liver Diseases, 2021)
• Vasoplegic syndrome after cardiovascular surgery: A review of pathophysiology and outcome-oriented therapeutic management (Journal of Cardiac Surgery, 2021)
• Vasoactive-Inotropic Score: Evolution, Clinical Utility, and Pitfalls (Journal of Cardiothoracic and Vascular Anesthesia, 2021)
• Management of noncytotoxic extravasation injuries: A focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline (Pharmacotherapy, 2023)
• An Update on Pharmacologic Management of Neonatal Hypotension: When, Why, and Which Medication (Children, 2024)